Data_Sheet_4_v1_The mTOR inhibitor rapamycin suppresses trigeminal neuropathic pain and p-MKK4/p-p38 mitogen-activated protein kinase-mediated microglial activation in the trigemin... by Ji-Hee Yeo (15288553)

Data_Sheet_2_v1_The mTOR inhibitor rapamycin suppresses trigeminal neuropathic pain and p-MKK4/p-p38 mitogen-activated protein kinase-mediated microglial activation in the trigemin... by Ji-Hee Yeo (15288553)

Data_Sheet_8_v1_The mTOR inhibitor rapamycin suppresses trigeminal neuropathic pain and p-MKK4/p-p38 mitogen-activated protein kinase-mediated microglial activation in the trigemin... by Ji-Hee Yeo (15288553)

Table_1_Age-Dependent Assessment of Genes Involved in Cellular Senescence, Telomere, and Mitochondrial Pathways in Human Lung Tissue of Smokers, COPD, and IPF: Associations With SA... by Krishna P. Maremanda (9356819)

“…Aging plays an important role in various infectious diseases including the SARS-CoV-2 infection. Lung immunoblot analysis of smokers, COPD and IPF subjects revealed increased abundance of proteases and receptor/spike protein like TMPRSS2, furin, and DPP4 in association with a slight increase in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor ACE2 levels.…”

Data_Sheet_7_v1_The mTOR inhibitor rapamycin suppresses trigeminal neuropathic pain and p-MKK4/p-p38 mitogen-activated protein kinase-mediated microglial activation in the trigemin... by Ji-Hee Yeo (15288553)

Data_Sheet_1_v1_The mTOR inhibitor rapamycin suppresses trigeminal neuropathic pain and p-MKK4/p-p38 mitogen-activated protein kinase-mediated microglial activation in the trigemin... by Ji-Hee Yeo (15288553)

Data_Sheet_3_v1_The mTOR inhibitor rapamycin suppresses trigeminal neuropathic pain and p-MKK4/p-p38 mitogen-activated protein kinase-mediated microglial activation in the trigemin... by Ji-Hee Yeo (15288553)

MicroRNA-215 Regulates Fibroblast Function: Insights from a Human Fibrotic Disease by Wanwen Lan (563363)

“…The effects of increased miR-215 were investigated by adding exogenous miR-215 to fibroblasts, and this showed a decrease in cell proliferation but no significant apoptosis compared to control. …”

Design of Ionic-Liquid-Based Hybrid Polymer Materials with a Magnetoactive and Electroactive Multifunctional Response by Liliana C. Fernandes (6711500)

“…The magnetic susceptibility of the [C<i>_n</i>mim]­[FeCl₄]/PVDF films reveals a paramagnetic behavior. The multifunctional response is characterized by a magnetoionic response that decreases with increasing IL alkyl chain length, the highest magnetoionic coefficient (1.06 ± 0.015 V cm^–1 Oe^–1) being observed for [C₂mim]­[FeCl₄]/PVDF. …”

Risk and protective factors for suicide: a populational case-control study, Brazil, 2019 by Ana Maria Pita Ruiz (14516702)

“…Higher district HDI levels also showed a 4% decrease in risk for each 0.01 increase in district HDI levels [OR = 0.02 (p = 0.008)]. …”

Image_4_Trends in Incidence and Mortality of Waldenström Macroglobulinemia: A Population-Based Study.TIF by Xuejiao Yin (5132441)

“…</p><p>Results: The incidence of WM showed an initial rapid increase from 1980 to 1993 {annual percentage change (APC), 14.1% [95% confidence interval (CI), 10 to 18.4%]}, whereas it began to stabilize from 1993 to 2016 [APC, 0.5% (95% CI, −0.3 to 1.3%)]. The WM IBM trend followed a similar pattern, with a decrease occurring around 1994. …”

Image_7_Trends in Incidence and Mortality of Waldenström Macroglobulinemia: A Population-Based Study.TIF by Xuejiao Yin (5132441)

“…</p><p>Results: The incidence of WM showed an initial rapid increase from 1980 to 1993 {annual percentage change (APC), 14.1% [95% confidence interval (CI), 10 to 18.4%]}, whereas it began to stabilize from 1993 to 2016 [APC, 0.5% (95% CI, −0.3 to 1.3%)]. The WM IBM trend followed a similar pattern, with a decrease occurring around 1994. …”

Image_6_Trends in Incidence and Mortality of Waldenström Macroglobulinemia: A Population-Based Study.TIF by Xuejiao Yin (5132441)

“…</p><p>Results: The incidence of WM showed an initial rapid increase from 1980 to 1993 {annual percentage change (APC), 14.1% [95% confidence interval (CI), 10 to 18.4%]}, whereas it began to stabilize from 1993 to 2016 [APC, 0.5% (95% CI, −0.3 to 1.3%)]. The WM IBM trend followed a similar pattern, with a decrease occurring around 1994. …”

Image_3_Trends in Incidence and Mortality of Waldenström Macroglobulinemia: A Population-Based Study.TIF by Xuejiao Yin (5132441)

“…</p><p>Results: The incidence of WM showed an initial rapid increase from 1980 to 1993 {annual percentage change (APC), 14.1% [95% confidence interval (CI), 10 to 18.4%]}, whereas it began to stabilize from 1993 to 2016 [APC, 0.5% (95% CI, −0.3 to 1.3%)]. The WM IBM trend followed a similar pattern, with a decrease occurring around 1994. …”

Image_2_Trends in Incidence and Mortality of Waldenström Macroglobulinemia: A Population-Based Study.TIF by Xuejiao Yin (5132441)

“…</p><p>Results: The incidence of WM showed an initial rapid increase from 1980 to 1993 {annual percentage change (APC), 14.1% [95% confidence interval (CI), 10 to 18.4%]}, whereas it began to stabilize from 1993 to 2016 [APC, 0.5% (95% CI, −0.3 to 1.3%)]. The WM IBM trend followed a similar pattern, with a decrease occurring around 1994. …”

Image_1_Trends in Incidence and Mortality of Waldenström Macroglobulinemia: A Population-Based Study.TIF by Xuejiao Yin (5132441)

“…</p><p>Results: The incidence of WM showed an initial rapid increase from 1980 to 1993 {annual percentage change (APC), 14.1% [95% confidence interval (CI), 10 to 18.4%]}, whereas it began to stabilize from 1993 to 2016 [APC, 0.5% (95% CI, −0.3 to 1.3%)]. The WM IBM trend followed a similar pattern, with a decrease occurring around 1994. …”

Image_3_Trends in Incidence and Mortality of Waldenström Macroglobulinemia: A Population-Based Study.TIF by Xuejiao Yin (5132441)

“…</p><p>Results: The incidence of WM showed an initial rapid increase from 1980 to 1993 {annual percentage change (APC), 14.1% [95% confidence interval (CI), 10 to 18.4%]}, whereas it began to stabilize from 1993 to 2016 [APC, 0.5% (95% CI, −0.3 to 1.3%)]. The WM IBM trend followed a similar pattern, with a decrease occurring around 1994. …”

Image_4_Trends in Incidence and Mortality of Waldenström Macroglobulinemia: A Population-Based Study.TIF by Xuejiao Yin (5132441)

“…</p><p>Results: The incidence of WM showed an initial rapid increase from 1980 to 1993 {annual percentage change (APC), 14.1% [95% confidence interval (CI), 10 to 18.4%]}, whereas it began to stabilize from 1993 to 2016 [APC, 0.5% (95% CI, −0.3 to 1.3%)]. The WM IBM trend followed a similar pattern, with a decrease occurring around 1994. …”

Image_2_Trends in Incidence and Mortality of Waldenström Macroglobulinemia: A Population-Based Study.TIF by Xuejiao Yin (5132441)

“…</p><p>Results: The incidence of WM showed an initial rapid increase from 1980 to 1993 {annual percentage change (APC), 14.1% [95% confidence interval (CI), 10 to 18.4%]}, whereas it began to stabilize from 1993 to 2016 [APC, 0.5% (95% CI, −0.3 to 1.3%)]. The WM IBM trend followed a similar pattern, with a decrease occurring around 1994. …”

Image_7_Trends in Incidence and Mortality of Waldenström Macroglobulinemia: A Population-Based Study.TIF by Xuejiao Yin (5132441)

“…</p><p>Results: The incidence of WM showed an initial rapid increase from 1980 to 1993 {annual percentage change (APC), 14.1% [95% confidence interval (CI), 10 to 18.4%]}, whereas it began to stabilize from 1993 to 2016 [APC, 0.5% (95% CI, −0.3 to 1.3%)]. The WM IBM trend followed a similar pattern, with a decrease occurring around 1994. …”